hypeless
Back to the news

Companies

Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'

Reported by: CNBC TV18 ·

WhatsApp

Gland Pharma

Summary

Gland Pharma shares rose 7% to a 52-week high on 9 November. Livemint reported the stock opened at ₹3,147 on NSE against a previous close of ₹3,132.80 and touched an intraday high of ₹3,352. This is the analysts' view, not Hypeless's. A 52-week high means the highest price the stock has traded at in the past year. Q2FY27 is the July to September quarter of the financial year ending March 2027. A valuation multiple is a measure of how the share price compares with a company's earnings. Livemint noted the stock has risen 93% so far this year.

AI summary of what CNBC TV18 and Livemint reported. AI can make mistakes. Read the full story on CNBC TV18

Learn: What is the P/E ratio?

Sources

Every outlet that reported this story. Each link opens the outlet's own article.

What each outlet wrote

The same news, in each outlet's own headline. Open one to read their full story.

CNBC TV18  · · Tone +2

Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'

Nomura believes the company's strong Q2FY27 performance, particularly the continued momentum in the US market, supports its growth outlook. It also sees scope for an expansion in the stock's valuation multiple,…

Some headlines quote an analyst. Those views are theirs, not ours.

Key terms

Words in this story, explained in plain language in our Learn pages.

  • Q2FY27

    Revenue, profit, margins and EPS: what the numbers in a quarterly result mean, why year-on-year and quarter-on-quarter differ, and what a headline can leave out.

    Learn: How to read a company's results

Earlier coverage

What outlets reported about the same company before this story, newest first.

Ask Hypeless about this story

Ask what it means, what a term in it means, or what other outlets said. Answers use only these outlets' headlines.

Ask Hypeless